N@N

AtCor Medical Holdings Ltd.: AtCor Medical Announces New Pharmaceutical and Biotech Clinical Trial Contracts

_{//business-finance.news-articles.net/content/200 .. utical-and-biotech-clinical-trial-contracts.html}
^{Published in Business and Finance on Wednesday, January 28th 2009 at 7:43 GMT, Last Modified on 2009-01-28 07:44:03 by Market Wire}  

ITASCA, IL and SYDNEY AUSTRALIA--(Marketwire - January 28, 2009) - AtCor Medical (ASX: [ ACG ]), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed new agreements to supply SphygmoCor systems and clinical trial support services to a US biotech company and a leading international pharmaceutical company. The minimum total value of these contacts is US $650,000 and US $210,000 respectively. These new orders bring the minimum total value of pharmaceutical clinical trial contracts secured by AtCor in the past eight months to over US $6.5 million.

Duncan Ross, CEO of AtCor Medical, said, "We continue to execute on our strategy, which is producing strong growth despite a tough macroeconomic environment. These new contracts show the increasing importance of SphygmoCor as a tool for understanding drug efficacy and mechanisms of action in pharmaceutical and biotechnology clinical trials, as well as SphygmoCor's significance as a drug therapy management tool in clinical practice. We look forward to continuing to build mutually beneficial relationships with our expanding list of clinical trials customers."

Mr. Ross added, "The growing use of SphygmoCor systems in clinical trials and the increasing volume of publications concerning central blood pressures and arterial stiffness continue the push towards establishment of a new standard for cardiovascular risk assessment and management."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,800 SphygmoCor systems are currently in use worldwide at major medical centers, research institutions and in clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in the United States, Australia and Europe. For further information, please visit our web site at [ www.atcormedical.com ].